Population-based screening with a prostate-specific antigen (PSA) test has been shown to reduce mortality in prostate cancer.1 However, the PSA test has limited sensitivity and specificity, resulting in missed early detection of significant cancers, unnecessary biopsies, and detection of indolent cancers. This evidence concerns the gene KLK3 and Familial prostate cancer.